160 related articles for article (PubMed ID: 24519555)
1. Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues.
Waser B; Reubi JC
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1166-71. PubMed ID: 24519555
[TBL] [Abstract][Full Text] [Related]
2. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.
Waser B; Reubi JC
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1054-8. PubMed ID: 21210113
[TBL] [Abstract][Full Text] [Related]
3. Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.
Rylova SN; Waser B; Del Pozzo L; Tönnesmann R; Mansi R; Meyer PT; Reubi JC; Maecke HR
J Nucl Med; 2016 Aug; 57(8):1282-8. PubMed ID: 27127218
[TBL] [Abstract][Full Text] [Related]
4. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
5. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.
Körner M; Stöckli M; Waser B; Reubi JC
J Nucl Med; 2007 May; 48(5):736-43. PubMed ID: 17475961
[TBL] [Abstract][Full Text] [Related]
7. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.
Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797
[TBL] [Abstract][Full Text] [Related]
8. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
9. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging.
Mukai E; Toyoda K; Kimura H; Kawashima H; Fujimoto H; Ueda M; Temma T; Hirao K; Nagakawa K; Saji H; Inagaki N
Biochem Biophys Res Commun; 2009 Nov; 389(3):523-6. PubMed ID: 19737540
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
12. Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor.
Kedees MH; Guz Y; Grigoryan M; Teitelman G
Peptides; 2013 Oct; 48():36-44. PubMed ID: 23927844
[TBL] [Abstract][Full Text] [Related]
13. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).
Fehmann HC; Jiang J; Schweinfurth J; Wheeler MB; Boyd AE; Göke B
Peptides; 1994; 15(3):453-6. PubMed ID: 7937318
[TBL] [Abstract][Full Text] [Related]
14. Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas.
Widmann C; Dolci W; Thorens B
Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):203-14. PubMed ID: 7646446
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.
Knudsen LB; Pridal L
Eur J Pharmacol; 1996 Dec; 318(2-3):429-35. PubMed ID: 9016935
[TBL] [Abstract][Full Text] [Related]
16. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
Li N; Lu J; Willars GB
PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
[TBL] [Abstract][Full Text] [Related]
17. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.
Brom M; Joosten L; Oyen WJ; Gotthardt M; Boerman OC
Contrast Media Mol Imaging; 2012; 7(2):160-6. PubMed ID: 22434628
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist.
Connolly BM; Vanko A; McQuade P; Guenther I; Meng X; Rubins D; Waterhouse R; Hargreaves R; Sur C; Hostetler E
Mol Imaging Biol; 2012 Feb; 14(1):79-87. PubMed ID: 21394533
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
20. Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.
Radziszewska E; Bojanowska E
Med Sci Monit Basic Res; 2013 Jan; 19():6-11. PubMed ID: 23291632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
